2016
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*
DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*. Leukemia & Lymphoma 2016, 58: 1325-1331. PMID: 27774847, PMCID: PMC5394924, DOI: 10.1080/10428194.2016.1246726.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeOverall survivalFemale patientsMDS Clinical Research ConsortiumLonger median OSFirst-line therapyClinical Research ConsortiumMedian OSBetter OSPatient sexCytidine deaminase activityPatientsResponse rateDifferential response ratesSignificant differencesSexResearch ConsortiumDeaminase activityDifferential responseBiological reasonsSyndromeTherapyDecitabineDifferences
2015
Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
DeZern A, Zeidan A, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz G, Komrokji R, Garcia-Manero G, Steensma D, Sekeres M. Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). Blood 2015, 126: 2889. DOI: 10.1182/blood.v126.23.2889.2889.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeMedian overall survivalBone marrow blastsFirst-line therapyOverall survivalTime of presentationMyelodysplastic syndromeMedian OSBlast percentageBetter OSMarrow blastsCytogenetic categoriesBone marrow blast percentageMDS Clinical Research ConsortiumStandard first-line therapyInternational Working Group criteriaCox PH analysisCox proportional analysisMarrow blast percentageSpeakers bureauClinical Research ConsortiumLog-rank testDate of deathFuture prospective investigationsMann-Whitney U test